Absolutely bearish on this. Their drug actually worsened outcomes in CKD (published in NEJM), and now they're trying to find a niche where increasing GFR will be sufficient.
The company claims they've identified the baseline characteristics of patients that were likely to be harmed by the drug. In effect, it was a subgroup that ostensibly drove the adverse events. Now they're omitting that subgroup in future trials.
It does raise one interesting question: are retrospectively defined subgroups more reliable for AEs than they are for efficacy going forward?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.